Followers | 218 |
Posts | 38765 |
Boards Moderated | 0 |
Alias Born | 04/29/2008 |
Saturday, August 20, 2016 7:29:46 PM
The stock is undervalued based on liquidation, but for whatever reason, the company decided to throw it's large cash reserve into acquiring another bio tech which needs cash. And all they get is 20% of the company for that cash. That values KalVista at about $175 million, which clearly the market thinks is too high.
Based on CBYL's current price, the market values KalVista at about $70 million.
Definitely not zero risk as KalVista is just starting its phase 1 clinical trials on their one drug and results won't be announced until Q2 2017.
TA - Over $500 million in toxic funded pump and dumps exposed and growing every day!
Recent KALV News
- KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology • Business Wire • 10/28/2024 10:30:00 AM
- KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) • Business Wire • 10/18/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:07:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:07:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:05:46 PM
- KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum • Business Wire • 10/04/2024 04:29:00 PM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/02/2024 10:30:00 AM
- KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema • Business Wire • 09/30/2024 10:30:00 AM
- KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) • Business Wire • 09/26/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 08:34:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 08:32:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 12:31:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:39:55 PM
- KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 11:00:00 AM
- KalVista Appoints Brian Piekos as Chief Financial Officer • Business Wire • 09/10/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 • Business Wire • 09/06/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:24:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/05/2024 08:07:47 PM
- KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update • Business Wire • 09/05/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/04/2024 10:30:00 AM
- KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema • Business Wire • 09/03/2024 10:30:00 AM
- KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium • Business Wire • 08/29/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 12:00:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 11:58:40 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM